MIRM Stock — Mirum Pharmaceuticals, Inc.: Metrics

Market overview

2 metrics

Share price

$99.83

Market cap

$6.39B

Price action

19 metrics

Price change (1W)

+0.3%

Price change (30D)

-6.0%

Price change (3M)

+6.7%

Price change (6M)

+12.0%

Price change (YTD)

+24.5%

Price change (1Y)

+33.1%

Trailing year

Price change (5Y)

+507.8%

52-week high

$128.57

52-week low

$64.10

Change from 52-week high

-23.5%

Change from 52-week low

+53.4%

Annualized volatility

45.7%

Beta

1.0

RSI (14D)

42.6

Price vs SMA 50

-10.5%

Price vs SMA 200

+2.8%

Avg volume (3M)

780,305

Relative volume

0.5

Average dollar volume

$84.60M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

64.93M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

10.3×

reciprocal yield 9.7%

P / book

—

FCF yield

-3.6%

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-13.5%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-08-05

Profitability

9 metrics

Gross margin

—

Operating margin

-134.9%

Trailing 12 months

Net margin

-139.2%

Gross profit (TTM)

—

Operating profit (TTM)

−$833.97M

Net income (TTM)

−$860.21M

Trailing 12 months

Diluted EPS (TTM)

$-14.54

FCF margin

-37.0%

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$-27.19

Growth

11 metrics

Revenue growth YoY

+37.9%

Year over year

Net income growth YoY

—

Revenue (TTM)

$618.07M

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+27.4%

Year over year · more shares

Revenue CAGR (3Y)

+89.1%

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

—

Return on assets

-82.3%

Debt / equity

—

Current ratio

2.9

EBITDA (TTM)

−$808.02M

Free cash flow (TTM)

−$228.74M

Quick ratio

2.7

Interest coverage

-62.1

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

$438.29M

Latest balance sheet

Cash & equivalents

$330.73M

Total assets

$1.04B

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$227.27M

Capital expenditures (TTM)

$1.47M

R&D (TTM)

$287.50M

SG&A (TTM)

$313.84M

Stock compensation (TTM)

$103.93M

R&D / revenue

46.5%

Stock compensation / revenue

16.8%

Ownership (13F)

3 metrics

13F filers

331

13F filer change QoQ

+17

Institutional ownership

110.2%

Short interest

3 metrics

Short interest

10.0%

Latest settlement · 7.3 days to cover

Days to cover

7.3d

Short-squeeze score

72 / 100

Insider activity

2 metrics

Net insider buying (90D)

−$10.89M

Insider-sentiment score

30 / 100

Risk flags

1 metrics

Going concern

—

MIRM · Mirum Pharmaceuticals, Inc.

MIRM metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search